Before you hand over a card, these are the questions that reveal what a program actually costs and how carefully it's run.
The information you need to choose well is rarely all on the pricing page. Asking the right questions directly — by message, chat or during your consult — surfaces the costs and quality signals that marketing leaves out. How a provider answers is itself informative: clear, specific answers signal a transparent operation; vague or evasive ones are a reason to look elsewhere.
• Does my monthly price change as my dose increases? What will I pay at 5, 10 and 15 mg?
• Is the price I see the ongoing price, or a promotional starter rate?
• What's the per-month price at each plan length, and what's due upfront?
These reveal the pricing model and your real annual cost. See why prices rise by dose.
• Are provider visits included, or billed per consult?
• Is lab review included, or do I arrange and pay for labs myself?
• Is shipping included? Is expedited or cold-chain shipping extra?
• Is coaching bundled or an add-on?
See what's included.
• Which pharmacy fills my prescription? Is it a 503A pharmacy or a 503B outsourcing facility?
• Can you provide a certificate of analysis for the medication?
• Who is the prescribing clinician, and are they licensed in my state?
• What follow-up is available for side-effects and titration?
See what pharmacy fills it and is it safe?
• What's the cancellation policy? Can I stop mid-plan?
• Is the unused portion of a longer plan refundable?
• What happens if I pause for a side-effect or a supply gap?
• Does the plan auto-renew, and how do I opt out?
A low annual price only helps if you can exit it on fair terms.
Run the same questions past every provider on your shortlist and line up the answers side by side. That converts marketing into a real comparison. For the framework behind it, see how to compare providers. This is educational guidance — whether the medication is appropriate for you is a decision for a licensed clinician.
Ask whether the price changes by dose, what's included (visits, labs, shipping), which pharmacy fills it and its 503A/503B status, whether there's genuine clinical follow-up, and the cancellation and refund terms.
Clear, specific answers about pricing at higher doses, the pharmacy, and cancellation terms signal transparency. Vague or evasive answers are a warning sign.
Yes. Because compounded tirzepatide isn't FDA-approved as a finished product, knowing the pharmacy and its 503A/503B status is a key quality and safety check.